PATENT CLAIM ANALYSIS

Application Number: 15908659
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["424", "178100"]

Abstract:
Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.

Claim (Index 45):
The method of  claim 44 , wherein said lymphoma or leukemia comprises chronic lymphocytic leukemia (CLL).

Metadata:
- Claim Count in Document: 23.0
- Percentile: 88.0
- Lexical Diversity: 1.39216
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14973486', '13703864', '15619119', '12545731', '14422519']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7827401314251227
- 35 USC 102 Novelty (BERT): 0.5905623548154634
- Combined Prediction Score: 0.7635223537641568
- Mean Citation Score: 450.89352
- Max Citation Score: 613.11084
- Similarity Product: 382.7922882079125

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test